Study Comparing Two Image Acquisition Modalities for Second-trimester Pregnancy Screening Ultrasound (Echo-IA)
Echo-IA
A Single-center Cross-sectional Study Comparing Two Image Acquisition Modalities for Second-trimester Pregnancy Screening Ultrasound.
1 other identifier
interventional
50
1 country
1
Brief Summary
The second-trimester morphology ultrasound is a key examination in obstetric monitoring that aims to assess fetal growth, identify any structural abnormalities, and inspect anexes such as placenta, umbilical cord, cervix,... Several studies suggest that a significant proportion of fetal malformations can be detected during this time frame if a complete morphological analysis is performed. However, the reliability of the screening depends on the quality of the equipment, the operator's level of expertise, and adherence to protocols that define the necessary scans. In France, since the first reports of the National Technical Committee on Prenatal Screening Ultrasound (2005), particular attention has been paid to standardizing practices. More recently, the French National Conference on Obstetric and Fetal Ultrasound (CNEOF) published new recommendations (2022, revised in 2023) including the development of reference silhouettes for the second-trimester examination, proposing 26 views (22 required and 4 additional). However, the CNEOF does not formalize quality criteria for evaluating the conformity of these images; this task has been taken over by the French College of Fetal Ultrasound (CFEF), which has established a scoring and validation grid for each fetal slice (see CFEF 2022 document). In parallel, artificial intelligence (AI) is gradually becoming established as a decision support and automation tool in medical imaging, particularly in ultrasound. Deep learning algorithms are capable of identifying anatomical structures, positioning measurement markers, and selecting the most optimal slice, reducing inter-operator variability and streamlining workflow. In the field of obstetric ultrasound, some companies have launched systems capable of detecting or annotating fetal structures in real time, potentially improving diagnostic reliability and reproducibility. Samsung has developed a system called Live View Assist, available on its latest generation ultrasound scanners, which uses AI to automatically recognize and freeze the required fetal slices in real time. The tool also offers automated validation: if the detected slice conforms to the expected standards, it is directly checked off on a checklist. This innovation promises time savings, a reduced risk of missing certain complex slices, and improved standardization. However, there is little data, particularly in France, regarding to the actual performance of this tool in a routine screening context. Before considering the integration of Live View Assist and AI into daily practice, it is therefore essential to evaluate the quality of the images it acquires, the feasibility of a complete examination assisted by AI, as well as the potential impact on examination time and improvement of the workload for sonographers. The aim of this study is to evaluate whether the quality of the 20 mandatory images automatically validated by Live View Assist is not inferior to that of the 20 mandatory images acquired and validated manually by an ultrasound technician, according to the CFEF quality criteria based on the silhouettes recommended by the CNEOF.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 27, 2025
CompletedStudy Start
First participant enrolled
December 15, 2025
CompletedFirst Posted
Study publicly available on registry
December 16, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 21, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2026
March 17, 2026
March 1, 2026
6 months
November 27, 2025
March 16, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Images deemed "acceptable"
Images deemed acceptable (i.e., for each image, all criteria are rated as good or acceptable, with none being insufficient or poor). To evaluate the primary objective, the statistical unit will be the image. All 20 mandatory images for each patient will be analyzed
through study completion, an average of 6 months
Study Arms (2)
Standard ultrasound
ACTIVE COMPARATORManual acquisition: acquisition of the 22 mandatory images and, if possible, the 4 additional images by the sonographer, respecting the standardized procedure derived from the CNEOF recommendations.
Artificial intelligence-assisted ultrasound
EXPERIMENTALAI-assisted acquisition: using the Live View Assist system to automatically capture the 20 mandatory views in real time, with validation and recording of images as soon as the algorithm detects an image conforming to the reference, and if possible the 2 complementary images.
Interventions
Eligibility Criteria
You may qualify if:
- Women aged 18 or over,
- With a single, viable pregnancy, definitively dated by first-trimester ultrasound, with no known malformations,
- Scheduled for a routine second-trimester screening ultrasound, i.e., between 20 weeks + 0 days and 24 weeks + 6 days,
- Having given their informed consent,
- Affiliated with the social security system or a beneficiary of such a plan.
You may not qualify if:
- Multiple pregnancy,
- Known fetal malformation,
- Pathological pregnancy,
- Cognitive impairment, or a disorder causing difficulty understanding instructions or answering questionnaires,
- Patient under legal guardianship,
- Patient not covered by health insurance,
- Protected patient: adult under guardianship, curatorship, or other legal protection, deprived of liberty by judicial or administrative decision
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Clinique Rive Gauche
Toulouse, 31300, France
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SCREENING
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 27, 2025
First Posted
December 16, 2025
Study Start
December 15, 2025
Primary Completion (Estimated)
June 21, 2026
Study Completion (Estimated)
June 30, 2026
Last Updated
March 17, 2026
Record last verified: 2026-03